54.48

0.85% 0.46

After Hours: 55.00 0.52 +0.95%

Monopar Therapeutics Inc (MNPR)

Overview News Price History Financials Discussions Forecast

Monopar Therapeutics Inc stock is traded at $54.48, with a volume of 78,415. It is up +0.85% in the last 24 hours and up +0.70% over the past month. Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Previous Close:

$54.02

Open:

$53.85

24h Volume:

78,415

Relative Volume:

0.37

Market Cap:

$364.59M

Revenue:

Net Income/Loss:

$-13.72M

P/E Ratio:

-27.43

EPS:

-1.9861

Net Cash Flow:

$-12.20M

1W Performance:

+3.36%

1M Performance:

+0.70%

6M Performance:

-31.83%

1Y Performance:

+33.50%

1-Day Range:

$53.65

$55.42

1-Week Range:

$50.22

$55.42

52-Week Range:

$28.40

$105.00

Monopar Therapeutics Inc Stock (MNPR) Company Profile

Name

Monopar Therapeutics Inc

Sector

Healthcare (1108)

Industry

Biotechnology (620)

Phone

(847) 388-0349

Address

1000 SKOKIE BLVD SUITE 350, WILMETTE

Employee

Twitter

Next Earnings Date

2026-05-12

Latest SEC Filings

MNPR's Discussions on Twitter

Compare MNPR vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MNPR Monopar Therapeutics Inc	54.48	361.51M	0	-13.72M	-12.20M	-1.9861
VRTX Vertex Pharmaceuticals Inc	430.14	108.36B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	731.77	78.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	775.03	48.74B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	302.11	41.16B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	298.16	33.17B	5.36B	287.73M	924.18M	2.5229

Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-09-26	Initiated	Morgan Stanley	Overweight
Nov-14-25	Downgrade	Raymond James	Strong Buy → Outperform
Nov-10-25	Initiated	Leerink Partners	Outperform
Oct-13-25	Initiated	Barclays	Overweight
Sep-09-25	Initiated	BTIG Research	Buy
Sep-03-25	Initiated	Oppenheimer	Outperform
Sep-03-25	Initiated	Raymond James	Strong Buy
Aug-26-25	Resumed	H.C. Wainwright	Buy
Jul-07-25	Initiated	Cantor Fitzgerald	Overweight
Jun-23-25	Initiated	Chardan Capital Markets	Buy
Mar-19-25	Resumed	Piper Sandler	Overweight
Jan-10-25	Initiated	Piper Sandler	Overweight
Oct-11-24	Initiated	Rodman & Renshaw	Buy
Jan-28-21	Initiated	ROTH Capital	Buy

View All

Monopar Therapeutics Inc Stock (MNPR) Latest News

Apr 26, 2026

(MNPR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Apr 26, 2026

Apr 22, 2026

MNPR (Monopar Therapeutics Inc.) slips 2.56% after Q4 2025 earnings miss on larger than expected per share loss.ROIC - Xã Thanh Hà

Apr 22, 2026

Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON) - The Globe and Mail

Apr 22, 2026

MNPR Stock Price, Quote & Chart | MONOPAR THERAPEUTICS INC (NASDAQ:MNPR) - ChartMill

Apr 22, 2026

Apr 21, 2026

Monopar Therapeutics stock maintained at Buy by Lake Street on trial data - Investing.com Canada

Apr 21, 2026

Apr 20, 2026

Monopar Therapeutics stock maintained at Buy by BTIG on trial data - Investing.com Canada

Apr 20, 2026

Monopar Reports Phase 3 Data Showing ALXN1840 Provides Greater Neurologic Benefit Versus Standard of Care in Wilson Disease Patients - Minichart

Apr 20, 2026

ALXN1840 Poised to Redefine Wilson Disease Treatment Standards: Phase 3 Success, De-Risked Profile, and Buy Rating Justification - TipRanks

Apr 20, 2026

Monopar Highlights Strong Phase 3 Data for ALXN1840 - TipRanks

Apr 20, 2026

Monopar (MNPR) unveils Phase 3 ALXN1840 neurologic gains and plans mid-2026 NDA - Stock Titan

Apr 20, 2026

Lake Street Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation - MSN

Apr 20, 2026

Monopar Therapeutics (MNPR) Shows Promising Results in Wilson Di - GuruFocus

Apr 20, 2026

Apr 19, 2026

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 - The Manila Times

Apr 19, 2026

Monopar Therapeutics Reports Positive Phase 3 Trial Results for ALXN1840 in Wilson Disease Patients at AAN Annual Meeting 2026 - Quiver Quantitative

Apr 19, 2026

Wilson disease study: 9% worsened on ALXN1840 vs 25% on standard care - Stock Titan

Apr 19, 2026

Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Apr 19, 2026

Apr 16, 2026

Monopar Therapeutics (MNPR) Stock Sector Perform (Weakens) 2026-04-16High Volume Stocks - Xã Vĩnh Công

Apr 16, 2026

Apr 15, 2026

How (MNPR) Movements Inform Risk Allocation Models - Stock Traders Daily

Apr 15, 2026

Apr 12, 2026

Chardan Capital Reaffirms Buy Rating on MNPR with $100 Price Tar - GuruFocus

Apr 12, 2026

Apr 11, 2026

Monopar Therapeutics (NASDAQ:MNPR) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat

Apr 11, 2026

Apr 10, 2026

Is Monopar Therapeutics Inc a momentum stock2026 Earnings Surprises & Weekly Top Gainers Trade List - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

Is Monopar Therapeutics Inc stock technically oversold2026 Risk Factors & Real-Time Chart Breakout Alerts - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

Q1 EPS Estimate for Monopar Therapeutics Boosted by Analyst - defenseworld.net

Apr 08, 2026

Apr 07, 2026